Intravenous aminophylline in the treatment of acute bronchospastic exacerbations of chronic obstructive pulmonary disease

Seidenfeld, John J.; Jones, William N.; Moss, Robert; Tremper, Joyce

doi:10.1016/s0196-0644(84)80472-2

Cited by 23 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All studies provided the standard deviation or standard error of the FEV 1 before treatment. One study provided the standard deviation for relative change in FEV 1 at two hours,10 one provided the SD for FEV 1 at two hours after treatment,8 and two provided an estimate of the variance for the absolute change in FEV 1 at three days 11 12. The two former studies were therefore not directly comparable, whereas the latter two were.…”

Section: Methodsmentioning

confidence: 99%

Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials

Barr

2003

BMJ

122

View full text Add to dashboard Cite

Objective To evaluate the addition of methylxanthines to standard treatments in patients presenting with acute exacerbations of chronic obstructive pulmonary disease (COPD). Design Meta-analysis of randomised controlled trials. Data source The Cochrane airways review group's COPD register. Two reviewers independently selected articles for inclusion, assessed methodological quality, and extracted data. Selection of studies Four trials met the inclusion criteria, with 169 patients. Main outcome measures Mean change in spirometry, clinical end points, symptom scores, and adverse events. Results Mean change in forced expiratory volume at one second at two hours was similar in methylxanthine and placebo groups but transiently increased with methylxanthines at three days. Non-significant reductions in admissions to hospital and length of stay were offset by a non-significant increase in relapses at one week. Changes in symptom scores did not reach significance. Methylxanthines caused more nausea and vomiting than placebo (odds ratio 4.6, 95% confidence interval 1.7 to 12.6), and non-significant increases in tremor, palpitations, and arrhythmias were also observed. Conclusions The available data do not support the use of methylxanthines for the treatment of exacerbations of chronic obstructive pulmonary disease. Potential benefits of methylxanthines for lung function and symptoms were generally not confirmed at standard levels of significance, whereas the potentially important adverse events of nausea and vomiting were significantly increased in patients receiving methylxanthines.

show abstract

Section: Methodsmentioning

confidence: 99%

Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials

Barr

2003

BMJ

122

View full text Add to dashboard Cite

show abstract

“…The addition of aminophylline to inhaled bronchodilators has not been shown to lead to improved FEV 1 but does increase frequency of side effects (166,167). For patients who are already on an oral methylxanthine product, it is reasonable to continue the medication during an AECB.…”

Section: Bronchodilator Therapymentioning

confidence: 99%

Canadian Guidelines for the Management of Acute Exacerbations of Chronic Bronchitis

Balter

Forge

Low

et al. 2003

Canadian Respiratory Journal

116

View full text Add to dashboard Cite

Acute exacerbations of chronic bronchitis (AECB) account for over 1.5 million physician visits annually in Canada and are a cause of significant morbidity and mortality. This document represents a joint effort between respirologists, microbiologists, infectious disease specialists and family physicians to update the Canadian AECB guidelines published in 1994. Treatment recommendations are graded on the strength of evidence in the published literature where possible. The role for oral corticosteroid therapy in preventing treatment failures, speeding up recovery and delaying the time to next exacerbation is discussed. Risk factors for treatment failure were used to stratify patients into risk groups to help guide antibiotic treatment recommendations. The importance of emerging antimicrobial resistance to current antibiotics is reviewed and strategies to prevent future AECB episodes are suggested.

show abstract

“…L'effet bronchodilatateur est supérieur à tous les autres bronchodilatateurs administrés par voie intraveineuse (bêta 2 -agonistes et théophylline). L'intérêt de la théophylline (aminophylline par voie injectable) comme bronchodilatateur additionnel est très discuté [27,28]. La fréquence d'effets indésirables rapportés, en particulier de nausées et de vomissements, est élevée [27,28].…”

Section: Bronchodilatateursunclassified

“…L'intérêt de la théophylline (aminophylline par voie injectable) comme bronchodilatateur additionnel est très discuté [27,28]. La fréquence d'effets indésirables rapportés, en particulier de nausées et de vomissements, est élevée [27,28]. [29] L'utilisation de nébuliseurs, des aérosols doseurs ou de poudres à inhaler est possible.…”

Section: Bronchodilatateursunclassified

Prise en charge des exacerbations aiguës de BPCO

Rabbat

Lorut

et al. 2010

Revue des Maladies Respiratoires

View full text Add to dashboard Cite

Intravenous aminophylline in the treatment of acute bronchospastic exacerbations of chronic obstructive pulmonary disease

Cited by 23 publications

References 14 publications

Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials

Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials

Canadian Guidelines for the Management of Acute Exacerbations of Chronic Bronchitis

Prise en charge des exacerbations aiguës de BPCO

Contact Info

Product

Resources

About